Fast and sustained efficacy of levetiracetam during titration and the first 3 months of treatment in refractory epilepsy

Epilepsia

Volumn 46, Issue 8, 2005, Pages 1304-1307

  French, Jacqueline ^a   Di Nicola, Sylvie ^b   Arrigo, Celestina ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Ariane II   (Belgium)

^c UCB PHARMA   (Belgium)

Author keywords

Levetiracetam; Outcome; Partial Seizures; Sustained efficacy

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM; DRUG DERIVATIVE; PIRACETAM; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EPILEPSY; FEMALE; FOCAL EPILEPSY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TITRIMETRY; COMPARATIVE STUDY; DRUG ADMINISTRATION; META ANALYSIS; PHASE 3 CLINICAL TRIAL; TIME; TREATMENT OUTCOME;

ADULT; ANTICONVULSANTS; CLINICAL TRIALS, PHASE III; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EPILEPSIES, PARTIAL; FEMALE; HUMANS; MALE; PIRACETAM; PLACEBOS; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS; TREATMENT OUTCOME;

EID: 23944500894     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2005.04005.x     Document Type: Article

References (15)

1. Ben-Menachem E, Falter U, for the European Levetiracetam Study Group. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 2000;41:1276-83.
2. Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000;55:236-42.
3. Shorvon SD, Löwenthal A, Janz D, et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 2000;41:1179-86.
4. Krakow K, Walker M, Otoul C, et al. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology 2001;56:1772-4.
5. Ben-Menachem E, Edrich P, Van Vleymen B, et al. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. Epilepsy Res 2003;53:57-64.
6. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000;83:77-85.
7. Patsalos PN. The pharmacokinetic characteristics of levetiracetam. Methods Find Exp Clin Pharmacol 2003;25:123-9.
8. French J, Arrigo C. Rapid onset of action of levetiracetam in refrac-tory epileptic patients. Epilepsia 2005;46:324-6.
9. Markham A, Adkins JC. Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma. Pharmacoeconomics 2000;18:591-608.
10. Leppik I, Morrel M, Godfroid P, et al. Seizure-free days observed in randomized placebo-controlled add-on trials with levetiracetam in partial epilepsy. Epilepsia 2003;44:1350-2.
11. Markowitz MA, Mauskopf JA, Halpern MT. Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy. Neurology 1995;51:1026-33.
12. Fuller WA, Kim JK. Hot deck imputation for the response model. Proc Stat Can Symp 2001;1-9.
13. Glien M, Brandt C, Potschka H, et al. Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe epilepsy. Epilepsia 2002;43:350-7.
14. Leite JP, Cavalheiro EA. Effects of conventional antiepileptic drugs in a model of spontaneous recurrent seizures in rats. Epilepsy Res 1995;20:93-104.
15. Doyle WK, Devinsky O, Luciano D, et al. Decreased seizure frequency after withdrawal and reinstitution of antiepileptic drug therapy. Seizure 1994;3:61-5.